Ovarian Cancer, Version 3.2022 Featured Updates to the NCCN Guidelines

Deborah K. Armstrong; Ronald D. Alvarez; Floor J. Backes; Jamie N. Bakkum-Gamez; Lisa Barroilhet; Kian Behbakht; Andrew Berchuck; Lee May Chen; Viola C. Chitiyo; Mihaela Cristea; Maria DeRosa; Eric L. Eisenhauer; David M. Gershenson; Heidi J. Gray; Rachel Grisham; Ardeshir Hakam; Angela Jain; Amer Karam; Gottfried E. Konecny; Charles A. Leath; Gary Leiserowitz; Joyce Liu; Lainie Martin; Daniela Matei; Michael McHale; Karen McLean; David S. Miller; Sanja Percac-Lima; Steven W. Remmenga; John Schorge; Daphne Stewart; Premal H. Thaker; Roberto Vargas; Andrea Wahner Hendrickson; Theresa L. Werner; Emese Zsiros; Mary A. Dwyer; Lisa Hang

doi:10.6004/jnccn.2022.0047

Ovarian Cancer, Version 3.2022 Featured Updates to the NCCN Guidelines

Deborah K. Armstrong, Ronald D. Alvarez, Floor J. Backes, Jamie N. Bakkum-Gamez, Lisa Barroilhet, Kian Behbakht, Andrew Berchuck, Lee May Chen, Viola C. Chitiyo, Mihaela Cristea, Maria DeRosa, Eric L. Eisenhauer, David M. Gershenson, Heidi J. Gray, Rachel Grisham, Ardeshir Hakam, Angela Jain, Amer Karam, Gottfried E. Konecny, Charles A. LeathGary Leiserowitz, Joyce Liu, Lainie Martin, Daniela Matei, Michael McHale, Karen McLean, David S. Miller, Sanja Percac-Lima, Steven W. Remmenga, John Schorge, Daphne Stewart, Premal H. Thaker, Roberto Vargas, Andrea Wahner Hendrickson, Theresa L. Werner, Emese Zsiros, Mary A. Dwyer, Lisa Hang

Research output: Contribution to journal › Article › peer-review

148 Scopus citations

Abstract

Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living .5 years following diagnosis. The NCCN Guidelines for Ovarian Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with ovarian, fallopian tube, and primary peritoneal cancers. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised guidance on alternative chemotherapy regimens for patients with advanced age and/or comorbidities, a new algorithm for recurrent low-grade serous carcinoma based on developing research and novel therapeutic agents, and updated language regarding tumor molecular analysis applications in ovarian cancer.

Original language	English
Pages (from-to)	973-980
Number of pages	8
Journal	JNCCN Journal of the National Comprehensive Cancer Network
Volume	20
Issue number	9
DOIs	https://doi.org/10.6004/jnccn.2022.0047
State	Published - Sep 2022

Access to Document

10.6004/jnccn.2022.0047

Cite this

Armstrong, D. K., Alvarez, R. D., Backes, F. J., Bakkum-Gamez, J. N., Barroilhet, L., Behbakht, K., Berchuck, A., Chen, L. M., Chitiyo, V. C., Cristea, M., DeRosa, M., Eisenhauer, E. L., Gershenson, D. M., Gray, H. J., Grisham, R., Hakam, A., Jain, A., Karam, A., Konecny, G. E., ... Hang, L. (2022). Ovarian Cancer, Version 3.2022 Featured Updates to the NCCN Guidelines. JNCCN Journal of the National Comprehensive Cancer Network, 20(9), 973-980. https://doi.org/10.6004/jnccn.2022.0047

@article{592e77c4980d48a08820c43f497cff9d,

title = "Ovarian Cancer, Version 3.2022 Featured Updates to the NCCN Guidelines",

abstract = "Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living .5 years following diagnosis. The NCCN Guidelines for Ovarian Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with ovarian, fallopian tube, and primary peritoneal cancers. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised guidance on alternative chemotherapy regimens for patients with advanced age and/or comorbidities, a new algorithm for recurrent low-grade serous carcinoma based on developing research and novel therapeutic agents, and updated language regarding tumor molecular analysis applications in ovarian cancer.",

author = "Armstrong, {Deborah K.} and Alvarez, {Ronald D.} and Backes, {Floor J.} and Bakkum-Gamez, {Jamie N.} and Lisa Barroilhet and Kian Behbakht and Andrew Berchuck and Chen, {Lee May} and Chitiyo, {Viola C.} and Mihaela Cristea and Maria DeRosa and Eisenhauer, {Eric L.} and Gershenson, {David M.} and Gray, {Heidi J.} and Rachel Grisham and Ardeshir Hakam and Angela Jain and Amer Karam and Konecny, {Gottfried E.} and Leath, {Charles A.} and Gary Leiserowitz and Joyce Liu and Lainie Martin and Daniela Matei and Michael McHale and Karen McLean and Miller, {David S.} and Sanja Percac-Lima and Remmenga, {Steven W.} and John Schorge and Daphne Stewart and Thaker, {Premal H.} and Roberto Vargas and Hendrickson, {Andrea Wahner} and Werner, {Theresa L.} and Emese Zsiros and Dwyer, {Mary A.} and Lisa Hang",

year = "2022",

month = sep,

doi = "10.6004/jnccn.2022.0047",

language = "English",

volume = "20",

pages = "973--980",

journal = "JNCCN Journal of the National Comprehensive Cancer Network",

issn = "1540-1405",

number = "9",

}

Armstrong, DK, Alvarez, RD, Backes, FJ, Bakkum-Gamez, JN, Barroilhet, L, Behbakht, K, Berchuck, A, Chen, LM, Chitiyo, VC, Cristea, M, DeRosa, M, Eisenhauer, EL, Gershenson, DM, Gray, HJ, Grisham, R, Hakam, A, Jain, A, Karam, A, Konecny, GE, Leath, CA, Leiserowitz, G, Liu, J, Martin, L, Matei, D, McHale, M, McLean, K, Miller, DS, Percac-Lima, S, Remmenga, SW, Schorge, J, Stewart, D, Thaker, PH, Vargas, R, Hendrickson, AW, Werner, TL, Zsiros, E, Dwyer, MA & Hang, L 2022, 'Ovarian Cancer, Version 3.2022 Featured Updates to the NCCN Guidelines', JNCCN Journal of the National Comprehensive Cancer Network, vol. 20, no. 9, pp. 973-980. https://doi.org/10.6004/jnccn.2022.0047

TY - JOUR

T1 - Ovarian Cancer, Version 3.2022 Featured Updates to the NCCN Guidelines

AU - Armstrong, Deborah K.

AU - Alvarez, Ronald D.

AU - Backes, Floor J.

AU - Bakkum-Gamez, Jamie N.

AU - Barroilhet, Lisa

AU - Behbakht, Kian

AU - Berchuck, Andrew

AU - Chen, Lee May

AU - Chitiyo, Viola C.

AU - Cristea, Mihaela

AU - DeRosa, Maria

AU - Eisenhauer, Eric L.

AU - Gershenson, David M.

AU - Gray, Heidi J.

AU - Grisham, Rachel

AU - Hakam, Ardeshir

AU - Jain, Angela

AU - Karam, Amer

AU - Konecny, Gottfried E.

AU - Leath, Charles A.

AU - Leiserowitz, Gary

AU - Liu, Joyce

AU - Martin, Lainie

AU - Matei, Daniela

AU - McHale, Michael

AU - McLean, Karen

AU - Miller, David S.

AU - Percac-Lima, Sanja

AU - Remmenga, Steven W.

AU - Schorge, John

AU - Stewart, Daphne

AU - Thaker, Premal H.

AU - Vargas, Roberto

AU - Hendrickson, Andrea Wahner

AU - Werner, Theresa L.

AU - Zsiros, Emese

AU - Dwyer, Mary A.

AU - Hang, Lisa

PY - 2022/9

Y1 - 2022/9

N2 - Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living .5 years following diagnosis. The NCCN Guidelines for Ovarian Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with ovarian, fallopian tube, and primary peritoneal cancers. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised guidance on alternative chemotherapy regimens for patients with advanced age and/or comorbidities, a new algorithm for recurrent low-grade serous carcinoma based on developing research and novel therapeutic agents, and updated language regarding tumor molecular analysis applications in ovarian cancer.

AB - Epithelial ovarian cancer is the leading cause of death from gynecologic cancer in the United States, with less than half of patients living .5 years following diagnosis. The NCCN Guidelines for Ovarian Cancer provide recommendations for the diagnosis, evaluation, treatment, and follow-up for patients with ovarian, fallopian tube, and primary peritoneal cancers. These NCCN Guidelines Insights summarize the panel discussion behind recent important updates to the guidelines, including revised guidance on alternative chemotherapy regimens for patients with advanced age and/or comorbidities, a new algorithm for recurrent low-grade serous carcinoma based on developing research and novel therapeutic agents, and updated language regarding tumor molecular analysis applications in ovarian cancer.

UR - http://www.scopus.com/inward/record.url?scp=85137540169&partnerID=8YFLogxK

U2 - 10.6004/jnccn.2022.0047

DO - 10.6004/jnccn.2022.0047

M3 - Article

C2 - 36075393

AN - SCOPUS:85137540169

SN - 1540-1405

VL - 20

SP - 973

EP - 980

JO - JNCCN Journal of the National Comprehensive Cancer Network

JF - JNCCN Journal of the National Comprehensive Cancer Network

IS - 9

ER -

Ovarian Cancer, Version 3.2022 Featured Updates to the NCCN Guidelines

Abstract

Access to Document

Other files and links

Fingerprint

Cite this